Richard Lake

11.2k total citations · 4 hit papers
135 papers, 8.3k citations indexed

About

Richard Lake is a scholar working on Immunology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Richard Lake has authored 135 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Immunology, 61 papers in Oncology and 50 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Richard Lake's work include Immunotherapy and Immune Responses (53 papers), Cancer Immunotherapy and Biomarkers (48 papers) and Occupational and environmental lung diseases (47 papers). Richard Lake is often cited by papers focused on Immunotherapy and Immune Responses (53 papers), Cancer Immunotherapy and Biomarkers (48 papers) and Occupational and environmental lung diseases (47 papers). Richard Lake collaborates with scholars based in Australia, United Kingdom and United States. Richard Lake's co-authors include Bruce Robinson, Anna K. Nowak, B. W. Robinson, Arthur W. Musk, W. Joost Lesterhuis, Bernadette Scott, Amanda L. Marzo, Robbert van der Most, Jenette Creaney and Edward J. Collins and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Richard Lake

130 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advances in Malignant Mesothelioma

2005 827 citations B. W. Robinson, Richard Lake profile →
Malignant mesothelioma

2005 533 citations Bruce Robinson, Arthur W. Musk et al. The Lancet profile →
Immunotherapy and chemotherapy — a practical partnership

2005 520 citations Richard Lake, Bruce Robinson profile →
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

2011 512 citations Jenette Creaney, Richard Lake et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Lake Australia	45	3.5k	3.4k	3.3k	1.4k	593	135	8.3k
Eugenie S. Kleinerman United States	51	2.8k 0.8×	2.4k 0.7×	2.4k 0.7×	3.2k 2.3×	347 0.6×	212	7.9k
Saburo Sone Japan	48	2.8k 0.8×	2.2k 0.6×	2.2k 0.7×	3.5k 2.5×	266 0.4×	259	8.2k
Michel Obéid Switzerland	22	4.2k 1.2×	3.5k 1.0×	1.1k 0.3×	1.5k 1.1×	260 0.4×	41	7.4k
Hua Liang China	29	4.1k 1.2×	4.1k 1.2×	1.2k 0.4×	2.2k 1.6×	194 0.3×	79	7.9k
Miguel F. Sanmamed Spain	40	5.6k 1.6×	5.0k 1.5×	1.5k 0.5×	2.5k 1.8×	275 0.5×	115	9.3k
Radek Špíšek Czechia	45	3.3k 1.0×	4.8k 1.4×	764 0.2×	1.9k 1.3×	304 0.5×	134	7.6k
Isabelle Cremer France	47	3.9k 1.1×	4.5k 1.3×	1.1k 0.3×	1.6k 1.1×	168 0.3×	89	7.4k
Thomas F. Gajewski United States	23	5.4k 1.6×	6.0k 1.8×	1.1k 0.3×	2.8k 2.0×	261 0.4×	33	9.4k
Dominic W. Chung United States	47	1.8k 0.5×	2.4k 0.7×	1.4k 0.4×	1.7k 1.2×	183 0.3×	101	8.1k
Eyad Elkord United Kingdom	41	4.3k 1.2×	3.9k 1.1×	1.1k 0.3×	2.2k 1.6×	215 0.4×	126	7.7k

Countries citing papers authored by Richard Lake

Since Specialization

Citations

This map shows the geographic impact of Richard Lake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Lake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Lake more than expected).

Fields of papers citing papers by Richard Lake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Lake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Lake. The network helps show where Richard Lake may publish in the future.

Co-authorship network of co-authors of Richard Lake

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Lake. A scholar is included among the top collaborators of Richard Lake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Lake. Richard Lake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zemek, Rachael M., Wee Loong Chin, Vanessa S. Fear, et al.. (2022). Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice. Nature Communications. 13(1). 4895–4895. 25 indexed citations

Tilsed, Caitlin M., Wee Loong Chin, Rachael M. Zemek, et al.. (2022). CD4+ T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy. Cell Reports. 41(13). 111874–111874. 8 indexed citations

Cook, Alistair, Alison M. McDonnell, Michael Millward, et al.. (2021). A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert Review of Anticancer Therapy. 21(5). 465–474.

Zemek, Rachael M., Vanessa S. Fear, Emma de Jong, et al.. (2020). Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. Nature Protocols. 15(5). 1628–1648. 17 indexed citations

Cook, Alistair, Louis Boon, Ian M. Dick, et al.. (2019). Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. OncoImmunology. 8(11). e1641390–e1641390. 26 indexed citations

Brims, Fraser, Tarek Meniawy, Duneesha de Fonseka, et al.. (2016). A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. Journal of Thoracic Oncology. 11(4). 573–582. 102 indexed citations

Cook, Alistair, W. Joost Lesterhuis, Anna K. Nowak, & Richard Lake. (2015). Chemotherapy and immunotherapy: mapping the road ahead. Current Opinion in Immunology. 39. 23–29. 110 indexed citations

Fisher, Scott, Andrea Khong, Ben Wylie, et al.. (2014). Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. Journal of Translational Medicine. 12(1). 245–245. 11 indexed citations

Nowak, Anna K., et al.. (2008). Cisplatin and pemetrexed synergises with immunotherapy to result in cures in established murine malignant mesothelioma. Cancer Research. 68. 2073–2073. 3 indexed citations

10.

Robinson, Cleo, Ivonne van Bruggen, Amanda Segal, et al.. (2006). A Novel SV40 TAg Transgenic Model of Asbestos-Induced Mesothelioma: Malignant Transformation Is Dose Dependent. Cancer Research. 66(22). 10786–10794. 65 indexed citations

11.

Holloway, Andrew, Dileepa Diyagama, Ken Opeskin, et al.. (2006). A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions. Clinical Cancer Research. 12(17). 5129–5135. 29 indexed citations

12.

Hayball, John D. & Richard Lake. (2005). The immune function of MHC class II molecules mutated in the putative superdimer interface. Molecular and Cellular Biochemistry. 273(1-2). 1–9. 10 indexed citations

13.

Robinson, Bruce, Arthur W. Musk, & Richard Lake. (2005). Malignant mesothelioma. The Lancet. 366(9483). 397–408. 533 indexed citations breakdown →

14.

Stumbles, Philip A., Robyn Himbeck, Jeffrey A. Frelinger, et al.. (2004). Cutting Edge: Tumor-Specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate to Mediate Tumor Regression following Systemic CD40 Activation. The Journal of Immunology. 173(10). 5923–5928. 50 indexed citations

15.

Nowak, Anna K., Richard Lake, Amanda L. Marzo, et al.. (2003). Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells. The Journal of Immunology. 170(10). 4905–4913. 361 indexed citations

16.

Robinson, Cleo, et al.. (2001). Private specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitis. Respiratory Research. 2(2). 119–24. 7 indexed citations

17.

Robinson, B. W., C. Robinson, & Richard Lake. (2001). Localised spontaneous regression in mesothelioma — possible immunological mechanism. Lung Cancer. 32(2). 197–201. 54 indexed citations

18.

Jones, Claerwen M., Richard Lake, Bhathiya Wijeyekoon, et al.. (1996). Oligoclonal v Gene Usage by T Lymphocytes in Bronchoalveolar Lavage Fluid from Sarcoidosis Patients. American Journal of Respiratory Cell and Molecular Biology. 14(5). 470–477. 16 indexed citations

19.

O’Hehir, Robyn E., et al.. (1996). Regulation of cytokine and chemokine transcription in a human TH₂ type T‐cell clone during the induction phase of anergy. Clinical & Experimental Allergy. 26(1). 20–27. 13 indexed citations

20.

HENDRY, W. F., Jitka Stedronska, & Richard Lake. (1982). Mixed erythrocyte-spermatozoa antiglobulin reaction (MAR test) for IgA antisperm antibodies in subfertile males. Fertility and Sterility. 37(1). 108–112. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact